Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click for my updated look at VIR ...

Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...

Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 ...